ProCE Banner Activity

REPRIEVE: Mechanistic Substudy of Effects of Pitavastatin on Plaque in People Living With HIV and Low-Moderate ASCVD Risk

Conference Coverage

In this analysis of the mechanistic substudy of the phase III REPRIEVE trial, the plaque-stabilizing effects of pitavastatin were predominantly mediated by PCOLCE, a rate-limiting enzyme involved in collagen deposition. There was no association between LDL change and noncalcified plaque volume.

Released: March 12, 2024

Expiration: March 11, 2025


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


This activity is supported through independent educational grants from Gilead Sciences, Inc., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare